|Proteome Sciences plc -- UK Stock|| |
GBp 3.07 0.03 0.97%
Chief Technical Officer of London Research Facility
Dr. Malcolm Ward is Chief Technical Officer London Research Facility of Proteome Sciences PLC. Malcolm Ward joined Proteome Sciences plc in May 2001 having previously worked for GlaxoWellcome for 12 years, in protein mass spectrometry. He was involved in the establishment of the new leading edge protein separation and mass spectrometry facility at the Institute of Psychiatry, Kings College London. His research team is involved in biomarker discovery, validation and assay development. His academic qualifications include a MS in Molecular Biology from the University of Hertfordshire in 1996 and a Graduateship from the Royal Society of Chemistry in 1992. He obtained a PhD in Applied Proteomics at Kings College, London in 2009..
Executive Since 2011
44 19 3286 5065 http://www.proteomics.com
The company has return on total asset (ROA)
of (20.17) %
which means that it has lost $20.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (16.4) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 8.93 M in total debt. Proteome Sciences plc has Current Ratio of 0.38 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
Proteome Sciences plc, a life sciences company, engages in the research and development of biomarkers. Proteome Sciences plc (PRM) is traded on London Stock Exchange in UK. It is located in Cobham, KT EP and employs 35 people.